5 Stocks to Watch: Week of 3/16/2026

Prep for the week ahead with five high-conviction stocks — all of these picks have A or B Ratings from our Zen Ratings system.

• AnaptysBio (ANAB) — FDA milestone could unlock 55% upside potential
• Ross Stores (ROST) — Discount retailer expanding fast near 52-week highs
• Broadcom (AVGO) — AI infrastructure giant trading 17% off its highs
• BrightSpring Health Services (BTSG) — Up 277% since listing and still climbing 
• Micron Technology (MU): The #1 semiconductor stock with 232% EPS growth projected

P.S. Missed last week’s picks? Get 'em here.

P.P.S. 10 Minutes a Month to Beat the Market … See the 11 Strategies Behind 44.4% Annual Returns and a 60.7% Breakout in 2025. Space is limited — claim your spot here.

A note from our sponsors...

1- Anaptysbio (NASDAQ: ANAB)

AnaptysBio is a clinical-stage biotech on the verge of a major catalyst — the FDA has accepted its application for a new medication for generalized pustular psoriasis, Q4 earnings beat estimates, and a strategic business separation is in the works to unlock even more value.

Zen Rating: Buy (B) — see full analysis

Recent Price: $63.79 — get current quote

Max 1-year forecast: $100.00

Why we're watching:

• Analyst support: ANAB enjoys a powerfully bullish consensus with 5 Strong Buy ratings and 2 Buy ratings among 7 analysts covering the stock. See the ratings
• For example, Barclays researcher Etzer Darout (a top 2% rated analyst) recently maintained his Strong Buy rating with a $79 price target following positive momentum. An increase in market share is anticipated following new product launches with market entry planned for Q4.
• Wells Fargo analyst Derek Archila (top 3%) also maintains a Strong Buy rating with an $81 price target.
• Industry ranking context: ANAB is currently the 11th highest-rated stock out of 472 in the Biotech industry — a strong position in a fairly weak industry.  
• Zen Rating highlights: Buy (B) stocks average +19.88%/yr — this is a high conviction stock among the thousands of stocks we track. 
• Component Grades: The company earns a B grade for Value and Financials, indicating solid fundamental strength despite operating in a challenging biotech sector with an F-rated industry backdrop. See all 7 Zen Component Grades here

2- Micron Technology (NASDAQ: MU)

Micron Technology sits at the top of the semiconductor industry — literally #1 — with a 38.4% profit margin and a stranglehold on the booming AI memory market. Here's why Wall Street's best analysts can't stop backing this stock.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $409.72 — get current quote

Max 1-year forecast: $550.00

Why we're watching:

• Analyst support: Wall Street shows overwhelming confidence with 17 Strong Buy ratings and 6 Buy ratings out of 24 total analysts, delivering a Strong Buy consensus. See the ratings
• UBS analyst Timothy Arcuri (a top 1% rated analyst) recently maintained his Strong Buy rating with a $475 price target, highlighting the company's strong positioning in the memory market.
• Multiple top-tier analysts including Quinn Bolton (Needham, top 1%), Joseph Moore (Morgan Stanley, top 1%), Vijay Rakesh (Mizuho, top 1%), and Kevin Cassidy (Rosenblatt, top 1%) all maintain bullish stances on the stock.
• In addition to these accolades, MU recently got high praise from our Zen Investor Editor in Chief Steve Reitmeister, who featured it in his video “My Top 10 Stocks I’d Bet My House On.”
• The company's explosive earnings growth trajectory forecasts EPS of $35.27 in one year (up 232%) and $48.07 in two years (up 352%), driven by surging demand for AI and data center memory solutions.
• Industry ranking context: MU is currently the 1st highest-rated stock in the Semiconductor industry, which has an Industry Rating of B.
• Zen Rating highlights: Only the top 5% of stocks in our 4600+ stock database boast an overall A or Strong Buy rating — MU is in this elite class. Learn more here
• Component Grades: Micron excels with an A grade in both Growth and Financials, complemented by B grades in Value, Momentum, and Sentiment, demonstrating comprehensive investment appeal. See all 7 Zen Component Grades here

3- Ross Stores (NASDAQ: ROST)

Ross Stores is doubling down on growth — with 17 new locations announced this month, the off-price retail giant behind Ross Dress for Less and dd's DISCOUNTS is riding a wave of momentum, and Wall Street analysts are upgrading the stock as confidence in its competitive edge grows.

Zen Rating: Buy (B) — see full analysis

Recent Price: $210.22 — get current quote

Max 1-year forecast: $245.00

Why we're watching:

• Analyst support: Strong Street backing with 8 Strong Buy ratings, 3 Buy ratings, and 2 Hold ratings among 13 analysts tracking the stock. See the ratings
• Telsey Advisory Group's Dana Telsey (a top 4% rated analyst) recently upgraded Ross to Buy with a $240 price target, signaling increased conviction in the off-price retailer's trajectory.
• Barclays analyst Adrienne Yih (top 4%) holds a Strong Buy rating with a $242 price target, representing 15.33% upside potential.
• Industry ranking context: Ross ranks 3rd in the Apparel industry, which carries a strong A Industry Rating, positioning it among sector leaders.
• Zen Rating highlights: Buy (B) stocks average +19.88%/yr, putting ROST in a class of stocks that have historically trounced the S&P.
• Component Grades: Ross earns B grades for Sentiment, and Financials, with a solid 49.34% return on equity demonstrating efficient capital deployment and strong operational execution. See all 7 Zen Component Grades here

A note from our sponsors...

4- Broadcom (NASDAQ: AVGO)

Broadcom is trading nearly 18% off its highs — and that dip could be a gift. The semiconductor and software powerhouse just launched its first 400G/lane optical DSP for next-gen AI networks, cementing its role as a critical backbone of the AI infrastructure boom.

Zen Rating: Buy (B) — see full analysis

Recent Price: $338.43 — get current quote

Max 1-year forecast: $582.00

Why we're watching:

• Analyst support: Overwhelming bullish sentiment with 17 Strong Buy ratings, 5 Buy ratings, and just 2 Hold ratings among 24 analysts. See the ratings
• Morgan Stanley's Joseph Moore (a top 1% rated analyst) recently maintained his Strong Buy rating with a $470 price target, citing robust earnings and strong growth forecasts with the company well-positioned to leverage market opportunities.
• Truist Securities researcher William Stein (top 1%) holds the most bullish target at $545, representing 62.22% upside, expressing confidence in future profitability and sustained growth drivers with expansion to new sectors anticipated.
• Citigroup analyst Atif Malik (top 1%) maintains a Strong Buy with a $475 target, noting Broadcom remains a critical player in the tech supply chain with substantial growth expected in earnings and revenue.
• Nancy Pelosi is a notable AVGO investor — and in case you didn’t know, she’s got a GREAT track record. Check out more of her holdings here.
• Industry ranking context: Broadcom ranks 9th in the Semiconductor industry, which has a B Industry Rating, positioning it among the elite in a high-growth sector.  
• Zen Rating highlights: Buy (B) rated stocks average +19.88%/yr — AVGO could even exceed this. Why? Several positive signs, like the fact that analysts project 49.06% earnings growth compared to 34.82% for the semiconductor industry and 36.28% market-wide.
• Component Grades: Broadcom ranks in the 80th percentile for Value, and the 85th percentile of stocks we track for Growth and Financials, demonstrating exceptional fundamental strength with 120.69% return on equity and 56.73% return on assets. See all 7 Zen Component Grades here

5- Brightspring Health Services (NASDAQ: BTSG)

A 277% return in just over two years — and BrightSpring Health Services is still climbing. Since its January 2024 listing, this home and community-based healthcare powerhouse has rewarded investors through relentless operational execution and strategic growth. Now ranked #5 in Health Information Services, BrightSpring is proving that betting on healthcare at home is paying off big. Here's why the momentum may just be getting started.

Zen Rating: B (Buy) — see full analysis

Recent Price: $38.54 — get current quote

Max 1-year forecast: $55.00

Why we're watching:

• Analyst support: Wall Street shows strong conviction with 7 Strong Buy ratings and 2 Buy ratings among 9 covering analysts, delivering an overwhelming Strong Buy consensus. See the ratings
• Morgan Stanley researcher Erin Wright (a top 5% rated analyst) recently maintained her Strong Buy rating with a $48 price target, representing nearly 24.22% upside potential.
• Mizuho analyst Ann Hynes (a top 12% rated analyst) recently maintained her Buy rating with a $50 price target, reflecting confidence in the company's growth trajectory.
• The company's earnings are projected to grow 47.5% over the next year to $1.39 per share, with continued expansion to $1.72 in year two, supported by strong revenue growth of 16.4% and expanding margins.
• Industry ranking context: BTSG is currently the 3rd highest-rated stock out of 45 in the Health Information Service industry, which has an Industry Rating of C.
• Zen Rating highlights: As a B or Buy-rated stock, BTSG has passed our 115-factor review with above-average marks that indicate it’s in a tier of stocks that have traditionally delivered nearly 20% annual returns. 
• Component Grades: The company excels with an A grade in Growth, along with B grades in Momentum, Sentiment and Safety, demonstrating solid operational execution and market momentum. See all 7 Zen Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.